VistaGen Therapeutics (VTGN) AI Stock Analysis

• Market Cap: $115.05M
• Dividend Yield: N/A
• Average Volume (3M): 611.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: -33.00%
• EPS Growth: 54.91%
• Country: US
• Employees: 48
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.47
• Shares Outstanding: 30,680,471
• 10 Day Avg. Volume: 519,111
• 30 Day Avg. Volume: 611,777
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.03
• Enterprise Value/Revenue: 4.70
• Enterprise Value/Gross Profit: 6.37
• Enterprise Value/Ebitda: -0.05
• 1Y Price Target: $14.33
• Price Target Upside: 263.71% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 55 Neutral
• Price Target: $4.50 ▲(14.21% Upside)

VistaGen Therapeutics' stock score is primarily influenced by its financial performance challenges, including consistent losses and negative cash flow. However, the technical analysis shows positive momentum, which provides some optimism. The valuation remains a concern due to the negative P/E ratio and lack of dividend yield. The company's advancements in clinical programs and strong equity position offer potential for future growth.

Positive Factors

Advancement of Clinical Programs

The advancement of clinical programs, especially intranasal fasedienol in Phase III trials, positions VistaGen for potential FDA approval, enhancing its market presence in treating social anxiety disorder.

Expansion of Product Pipeline

Expanding the product pipeline with candidates like Itruvone and PH80 diversifies VistaGen's portfolio, potentially increasing future revenue streams and reducing dependency on a single product.

Strong Financial Position

A robust cash position provides VistaGen with the financial stability needed to sustain R&D efforts and support long-term strategic initiatives without immediate liquidity concerns.

Negative Factors

Increased Research and Development Expenses

Rising R&D expenses, while necessary for growth, strain financial resources and may delay profitability, impacting long-term financial health if not managed efficiently.

Net Loss Increase

An increasing net loss indicates operational inefficiencies and financial strain, which could hinder VistaGen's ability to invest in growth and innovation over time.

Site Termination in Clinical Trials

The termination of a clinical trial site due to conduct issues may delay trial progress and reflects potential operational challenges, impacting the timeline for product development.

VistaGen Therapeutics Business Overview & Revenue Model

Company Description

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

How the Company Makes Money

VistaGen Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company may receive funding through various sources, including government grants, partnerships with pharmaceutical companies, and potential milestone payments tied to the progress of its drug candidates in clinical trials. Additionally, VistaGen may generate revenue through licensing agreements or collaborations that allow other companies to develop or market its products. As the company advances its drug candidates through clinical trials and approaches regulatory approval, potential sales from these products could become significant revenue streams.

VistaGen Therapeutics Financial Statement Overview

Summary

VistaGen Therapeutics faces significant challenges with consistent losses and negative cash flow. However, a strong equity position and manageable debt levels provide some stability. While the revenue growth shows potential, the company must focus on improving operational efficiency and profitability to ensure long-term success.

Income Statement

The company's revenue growth has been volatile, with a significant drop this year compared to the previous year. Gross profit margin remains stable due to the low cost structure, but the net profit margin is severely negative. The EBIT and EBITDA margins are also deeply negative, indicating operational inefficiency. Despite these challenges, there is a slight increase in revenue compared to the previous year, showing potential for future growth.

Balance Sheet

VistaGen Therapeutics has a relatively low debt-to-equity ratio, indicating a conservative capital structure. However, the return on equity is negative, impacted by consistent net losses. The equity ratio is strong, suggesting financial stability and a solid foundation for future growth. Despite these strengths, the company needs to improve profitability to leverage its equity effectively.

Cash Flow

The company's free cash flow is negative but shows improvement from the previous year, suggesting progress towards better cash management. Operating cash flow remains negative, but the ratio to net income indicates that cash losses are less severe than income losses. Continued focus on reducing cash burn is crucial for future financial health.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	646.00K	486.00K	1.06M	-227.00K	1.11M	1.09M
Gross Profit	477.00K	486.00K	1.06M	-227.00K	1.11M	1.09M
EBITDA	-58.28M	-55.34M	-32.45M	-58.74M	-47.05M	-17.44M
Net Income	-55.78M	-51.42M	-29.36M	-59.25M	-47.76M	-17.93M
Balance Sheet
Total Assets	68.92M	84.34M	123.65M	21.09M	74.64M	108.28M
Cash, Cash Equivalents and Short-Term Investments	63.18M	80.48M	119.17M	16.64M	68.14M	103.11M
Total Debt	2.36M	1.51M	2.12M	2.72M	3.04M	3.72M
Total Liabilities	12.16M	13.95M	9.37M	9.01M	9.93M	16.30M
Stockholders Equity	56.77M	70.39M	114.29M	12.08M	64.72M	91.98M
Cash Flow
Free Cash Flow	-50.12M	-42.29M	-25.87M	-49.93M	-45.46M	-12.35M
Operating Cash Flow	-50.07M	-42.10M	-25.81M	-49.72M	-45.26M	-12.07M
Investing Cash Flow	-8.47M	-13.15M	-61.00K	-740.30K	-200.40K	-275.40K
Financing Cash Flow	4.61M	3.21M	128.40M	-1.04M	10.48M	114.10M

VistaGen Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.94
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTGN, the sentiment is Positive. The current price of 3.94 is below the 20-day moving average (MA) of 4.04, above the 50-day MA of 3.64, and above the 200-day MA of 2.83, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 51.89 is Neutral, neither overbought nor oversold. The STOCH value of 20.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTGN.

VistaGen Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VTGN	―	$115.05M	―	―	―	-33.00%	54.91%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OVID	―	$98.84M	-2.59	-52.77%	―	1071.91%	-27.61%
SPRO	―	$136.75M	-2.48	-94.59%	―	-67.67%	-390.60%
MGNX	―	$104.92M	―	-69.71%	―	303.47%	73.70%
IKT	―	$114.76M	-1.42	-97.49%	―	-100.00%	62.82%
SRZN	―	$117.84M	-0.99	-130.27%	―	―	35.81%

VistaGen Therapeutics Corporate Events

VistaGen Therapeutics CFO Resignation Announced

VistaGen Therapeutics announced the resignation of its Chief Financial Officer, Cynthia L. Anderson, effective October 15, 2025. The company is searching for her successor and plans to retain her as a consultant to ensure a smooth transition. Additionally, at the 2025 Annual Meeting of Stockholders held on September 9, 2025, VistaGen’s stockholders elected six directors to the Board, approved executive compensation, and ratified KPMG LLP as the independent auditor for the fiscal year ending March 31, 2026.

The most recent analyst rating on (VTGN) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.

Vistagen Therapeutics’ Earnings Call: Progress Amid Challenges

Vistagen Therapeutics Inc. recently held its earnings call, which painted a picture of both optimism and caution. The company showcased significant progress in its clinical programs and strategic pipeline expansion, suggesting a strong potential for future success. However, concerns were raised due to increased research and development expenses, a higher net loss, and challenges with site termination.

Vistagen Therapeutics Reports Progress in Clinical Trials

Vistagen Therapeutics Inc., a late clinical-stage biopharmaceutical company, is pioneering neuroscience with its development of intranasal pherine product candidates targeting psychiatric, women’s health, and cancer supportive care sectors.

VistaGen Reports Q1 2026 Financial Results and Update

On August 7, 2025, Vistagen reported its fiscal year 2026 first-quarter financial results and provided a corporate update. The company highlighted the progress of its lead program, fasedienol, for treating social anxiety disorder, with key trial results expected in late 2025 and early 2026. Vistagen is optimistic about the potential impact of fasedienol, as there is currently no FDA-approved acute treatment for social anxiety disorder. The company is also advancing other intranasal pherine product candidates for major depressive disorder and women’s health conditions. Financially, Vistagen reported increased R&D expenses due to its ongoing trials and a net loss of $15.1 million for the quarter ended June 30, 2025.

The most recent analyst rating on (VTGN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.